港股異動 | 再鼎醫藥盤中升7% 中期營收增長近4成 虧損大幅收窄
再鼎醫藥(9688.HK)拉昇一度升至7%,現報19.5港元,總市值192.7億港元。公司上半年錄得總收入增加38.7%至1.32億美元,虧損淨額減少22.8%至1.7億美元。其中,產品收入增加40.6%至1.317億美元。公司研發開支持續加碼,同比增加4.3%至1.25億美元。截至2023年8月1日,公司在大中華區及美國有十三種候選產品正在進行後期臨牀開發,多種其他候選產品正在進行臨牀及臨牀前開發。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.